Faculty and Graduate School of Pharmacy, Division of Clinical Sciences and Neuropsychopharmacology, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya, Japan
Dr Kato is an eminent researcher. He is currently working as a Faculty and Graduate School of Pharmacy, Division of Clinical Sciences and Neuropsychopharmacology, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya, Japan. His research interests are in the field of Pharmacokinetics, Pharmaceutical Management, Drug Delivery, Drug Safety .
Research
Association Study between Genes Related to Pharmacokinetics and
Pharmacodynamics of Oxycodone and Response to Drug Treatment: A
Genetic Cohort Study
Author(s): Yoshimi A, Yoshijima Y, Miyazaki M, Kato H, Kato YK, Yamada K, Ozaki N, Kaneko R, Ishii A, Mitsuma A, Sugishita M, Ando Y and Noda Y*
Objective: Oxycodone is widely used in cancer patients with pain, but interindividual differences in both its analgesic efficacy and adverse effects are major clinical disadvantages to therapeutic use. To explore specific polymorphisms affecting drug plasma concentrations, analgesic efficacy, and adverse effects, we performed an association study between genetic polymorphisms affecting pharmacokinetics and pharmacodynamics of oxycodone and response to drug treatment in cancer patients with pain.
Methods: Blood samples were collected from 50 patients 12 h after administration of oxycodone. Genetic polymorphisms related to the pharmacokinetics and pharmacodynamics of oxycodone [cytochrome P450 (CYP3A4*1G, CYP3A5*3, and CYP2D6*10), P-glycoprotein (ABCB1), and opioid receptor μ1 (OPRM1)] were genotyped by real-time polymerase chain.. View more»